The utilization of pharmaceutical cannabinoid agents in Manitoba, Canada. A population-based study using administrative health care data.
Date
2019-02
Authors
Alkabbani, Wajd
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction: Pharmaceutical cannabinoids are third-line therapeutic options for several indications, despite the lack of strong evidence to support their efficacy. The extent and patterns of their utilization from a population perspective are unknown.
Methods: A retrospective population-based study using administrative healthcare data from Apr.1, 2004 to Mar.31, 2017, to assess the annual trends, demographic and clinical determinants, and persistence of pharmaceutical cannabinoids use.
Results: The incident and prevalent users of cannabinoid agents increased throughout the study period. Nabilone comprised the majority of dispensations. The percent of users who had a diagnosis for the approved indications was relatively low. Persistence of cannabinoid use was low and influenced by the socio-demographics and medical conditions of users.
Conclusion: Although the rates of pharmaceutical cannabinoid use have increased, the overall low numbers of users and the high discontinuation rates reflect the lack of effectiveness and tolerability to these agents.
Description
Keywords
Drug utilization, Cannabinoids, pharmacoepidemiology, Administrative data
Citation
Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton JM, Sareen J, Leong, C. Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open. 2018;6(4):E637-E642.